Related Experiment Videos
Efficacy of celiprolol in the elderly hypertensive patient
1University Department of Cardiovascular Studies, General Infirmary, Leeds, United Kingdom.
Insights
Celiprolol effectively manages cardiovascular risk factors in elderly hypertensive patients. This selective beta-blocker offers unique benefits for older adults with high blood pressure.
Area of Science:
- Cardiology
- Geriatrics
- Pharmacology
Background:
- Cardiovascular diseases are a leading cause of death and disability in the aging Western population.
- Effective management of cardiovascular risk factors is crucial for elderly patient care.
- Identified risk factors include hypertension, hyperlipidemia, glucose intolerance, and hyperfibrinogenemia.
Purpose of the Study:
- To review the impact of celiprolol on cardiovascular risk factors in elderly hypertensive patients.
- To highlight the unique pharmacologic profile of celiprolol for antihypertensive therapy in the elderly.
Main Methods:
- Review of existing evidence on celiprolol's effects.
- Analysis of celiprolol's pharmacologic properties (selective beta-1 antagonism, beta-2 agonism, vasodilation).
Main Results:
- Celiprolol demonstrates a unique and advantageous profile for treating hypertension in the elderly.
- The drug can significantly influence key cardiovascular risk factors amenable to pharmacologic intervention.
Conclusions:
- Celiprolol offers particular benefits for elderly hypertensive patients.
- Modern drug therapy, exemplified by celiprolol, plays a vital role in managing cardiovascular risk in older adults.
Abstract:
With the rapidly increasing average age of the population of the Western world, care and treatment of the elderly are becoming increasingly important. Cardiovascular diseases are major causes of death and disability in the elderly; hence, identification of cardiovascular risk factors and effective treatment are essential. Evidence indicates that these risk factors in the elderly are similar to those in the young; namely, high blood pressure, hyperlipidemia, glucose intolerance, hyperfibrinogenemia, obesity, and cigarette smoking. The latter two relate to general patient management, whereas the remainder can be significantly influenced by modern drug therapy such as celiprolol. This drug is a third-generation highly selective beta 1-adrenoceptor antagonist with beta 2-agonist and vasodilatory activity giving a unique and advantageous pharmacologic profile for antihypertensive therapy with particular benefits for the elderly. The impact of therapy with celiprolol on the cardiovascular risk factors in the elderly hypertensive patient is reviewed.